COMPARISON

Motixafortide vs Plecanatide

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

Motixafortide is authorised or registered in 2 and Plecanatide in 2 of the 10 registers read. Motixafortide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). Plecanatide: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

MotixafortidePlecanatide
Registered trials
differs
11
clinicaltrials.gov · 2026-10-03
15
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: APHEXDA
openfda · 2026-10-03T17:23:44.062Z
FDA-approved: Trulance Immediate release
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectMotixafortideplaceboPlecanatideplacebo
Leukocytosis98.6%0.0%--
Injection site pain93.2%27.8%--
Injection site erythema78.1%11.1%--
Pruritus61.6%0.0%--
Urticaria49.3%0.0%--
Injection site pruritus46.6%8.3%--
Flushing42.5%0.0%--
Injection site induration37.0%13.9%--
Feeling hot35.6%0.0%--
Paraesthesia27.4%0.0%--
Diarrhoea--5.8%1.2%
Headache--2.3%1.6%

Trial register Motixafortide: 1 placebo-controlled trials; Plecanatide: 8. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Motixafortide side effects · Plecanatide side effects

LEGAL STATUS

Approval in each country read

CountryMotixafortidePlecanatideRegister
United StatesFDA-approvedFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerNot on the registerRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerNot on the registerRegulator Swissmedic
BrazilNot on the registerNot on the registerRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeRegisteredNot on the registerRegulator HSA
TurkeyNot on the registerNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.